[Federal Register Volume 90, Number 192 (Tuesday, October 7, 2025)]
[Presidential Documents]
[Pages 48153-48155]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-19495]
[[Page 48151]]
Vol. 90
Tuesday,
No. 192
October 7, 2025
Part II
The President
-----------------------------------------------------------------------
Executive Order 14355--Unlocking Cures for Pediatric Cancer With
Artificial Intelligence
Presidential Documents
Federal Register / Vol. 90 , No. 192 / Tuesday, October 7, 2025 /
Presidential Documents
___________________________________________________________________
Title 3--
The President
[[Page 48153]]
Executive Order 14355 of September 30, 2025
Unlocking Cures for Pediatric Cancer With
Artificial Intelligence
By the authority vested in me as President by the
Constitution and the laws of the United States of
America, it is hereby ordered:
Section 1. Purpose and Policy. My Administration is
committed to driving innovation to prevent and treat
childhood diseases, including through the use of
artificial intelligence (AI). Pediatric cancer remains
the leading cause of disease-related death for children
in the United States aged 1-19 years, and its incidence
has increased by more than 40 percent since 1975.
As outlined in my joint address to the Congress in
March, reversing this trend is one of the top
priorities for the Make America Healthy Again (MAHA)
Commission established in Executive Order 14212 of
February 13, 2025 (Establishing the President's Make
America Healthy Again Commission). AI presents an
opportunity to more quickly achieve this aim.
In 2019, my Administration created the Childhood Cancer
Data Initiative (CCDI), a Federal investment in
childhood cancer research of $50 million in funding
every year for 10 years to address the critical need to
collect, generate, and analyze childhood cancer data.
The CCDI is building a foundational data
infrastructure, aggregating and generating new data,
and using this data to make new discoveries.
AI can be used to build upon this data initiative to
produce meaningful solutions to pediatric, adolescent,
and young adulthood cancer. This application of AI has
the potential to transform the Nation's current care
and research approach for pediatric cancer--as well as
our healthcare and research infrastructure more
broadly--through use of the rich and multimodal data,
secured with appropriate individual privacy
protections, to develop early and superior diagnostics,
identify cures and optimize treatments, and advance
medicine that will save lives.
For too long, we have watched our children and their
families battle cancer and its long-term chronic
effects while healthcare systems often rely on outdated
technologies and can be slow to adopt certain
innovations. We must prioritize investment in AI-
enabled science, build world-class scientific datasets,
and empower researchers and clinicians with the tools
needed to translate data and AI capabilities into
improved care.
Sec. 2. Harnessing American AI Innovation. The MAHA
Commission, in coordination with the Secretary of
Health and Human Services (Secretary), the Assistant to
the President for Science and Technology (APST), and
the Special Advisor for AI and Crypto, and in alignment
with the implementation of America's AI Action Plan,
shall work to develop innovative ways to utilize
advanced technologies such as AI to unlock improved
diagnoses, treatments, cures, and prevention strategies
for pediatric cancer. The initial focus shall be on
identifying opportunities to accelerate the progress of
AI-driven solutions at the CCDI, including by making
data platforms and tools available as part of the CCDI
Data Ecosystem and funding research projects at
National Cancer Institute-Designated Cancer Centers
that prioritize:
(a) improving data infrastructure by consolidating
data from multiple sources for AI-ready analysis and
utilizing AI to better select participants for clinical
trials;
[[Page 48154]]
(b) enhancing data analysis of complex biologic
systems with AI tools to radically improve predictive
modeling of patient response, disease progression, and
treatment toxicity and to turn multi-omics data and
imaging data into novel diagnostic, prognostic, and
therapeutic biomarkers; and
(c) improving clinical trial design, access, and
outcomes for patients by incorporating multimodal data
and using AI approaches to maximize utilization of the
information from clinical trials and improve
accessibility, recruitment, administration, conduct,
and interpretation of clinical trial results.
Sec. 3. Increasing Investment and Engagement in
Pediatric Cancer Research and Care Infrastructure. The
MAHA Commission, in coordination with the Secretary,
the Director of the Office of Management and Budget,
the Director of the National Institutes of Health, and
the APST, shall prioritize expanding pediatric cancer
research and advancements in care by identifying and
implementing strategies for:
(a) increasing investment from existing Federal
funds for the CCDI and other Federal Government
initiatives that address pediatric cancer; and
(b) encouraging the private sector to make use of
the most advanced technologies to unlock cures for
pediatric cancer, including those based on AI, to the
maximum possible extent.
Sec. 4. Improving Data Sharing and Empowering Patients.
The Secretary, in consultation with the APST, shall
work to ensure that AI innovation is appropriately
integrated into current work on interoperability to
maximize the potential for electronic health record and
claims data to inform private sector and academic
research and clinical trial design, while ensuring that
patients and parents control their health information.
In addition, the Secretary shall work to finalize
interoperability standards for patient data to be used
with AI that appropriately account for structured and
unstructured data and enable safe and privacy-compliant
exchanges of data.
Sec. 5. Definition. For the purposes of this order,
``artificial intelligence'' or ``AI'' has the meaning
set forth in 15 U.S.C. 9401(3).
Sec. 6. General Provisions. (a) Nothing in this order
shall be construed to impair or otherwise affect:
(i) the authority granted by law to an executive department or agency, or
the head thereof; or
(ii) the functions of the Director of the Office of Management and Budget
relating to budgetary, administrative, or legislative proposals.
(b) This order shall be implemented consistent with
applicable law and subject to the availability of
appropriations.
(c) This order is not intended to, and does not,
create any right or benefit, substantive or procedural,
enforceable at law or in equity by any party against
the United States, its departments, agencies, or
entities, its officers, employees, or agents, or any
other person.
[[Page 48155]]
(d) The costs for publication of this order shall
be borne by the Department of Health and Human
Services.
(Presidential Sig.)
THE WHITE HOUSE,
September 30, 2025.
[FR Doc. 2025-19495
Filed 10-6-25; 11:15 am]
Billing code 4150-28-P